Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth

Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth

Thioredoxin Reductase (TrxR) functions to recycle thioredoxin (Trx) during hydroperoxide metabolism mediated by peroxiredoxins and is currently being targeted using the FDA-approved anti-rheumatic drug, auranofin (AF), to selectively sensitize cancer cells to therapy. AF treatment decreased TrxR act...

Full description

Saved in:
Bibliographic Details
Main Authors: Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Casey Pulliam, Keegan A. Christensen, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Cancer Biology & Therapy
Subjects:
auranofin
sorafenib
small cell lung cancer
thioredoxin reductase
lung neuroendocrine tumor
dms273
Online Access:https://www.tandfonline.com/doi/10.1080/15384047.2024.2382524
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items